Pharma multi-national Astra Zeneca has reported total revenue in the year to date of $25.4bn, representing growth of 32%.
This figure included contributions from Alexion from late July 2021, following Astra Zeneca’s acquisition of the US-based immunology specialist.
Astra Zeneca said total revenue in the third quarter increased by 50% to $9.86bn – and excluding the pandemic Covid-19 vaccine, total revenue increased 21% in the year to date to $23.18bn and by 34% in the quarter to $8.81bn.
Gross profit up 14%
Astra Zeneca said year-to-date gross profit was $17.59bn, 14% up on the same period in 2020 when it hit $15.43bn.
In its trading statement, Astra Zeneca said it continued to recognise the heightened risks and uncertainties from the effects of Covid-19. “Variations in performance between quarters can be expected to continue,” the company said.
Perhaps reflecting these uncertainties, Astra Zeneca’s stock price was down 3.47% in early morning trading to 9,116.74p.
In addition to the improved figures for the year to date, the company highlighted eight positive Phase III trial results since June, with the potential to change the standard of care in several diseases.
Good pipeline delivery
Commenting on today’s third-quarter results, Astra Zeneca CEO Pascal Soriot commented: “AstraZeneca’s scientific leadership continues to provide strong revenue growth and exceptional pipeline delivery, with eight positive late-stage readouts across seven medicines since June, including our long-acting antibody combination showing promise in both prevention and treatment of Covid-19.
“The addition of Alexion furthers our commitment to bring transformative therapies to patients around the world, and I am proud of our colleagues’ ongoing dedication and focus.”
He added: “Our broad portfolio of medicines and diversified geographic exposure provides a robust platform for long-term sustainable growth. Following accelerated investment in upcoming launches after positive data flow, we expect a solid finish to the year.”
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.